Abu-Amna Mahmoud, Awadie Halim, Bar-Sela Gil
Division of Oncology, Rambam-Health Care Campus and Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel.
Department of Gastroenterology, Rambam-Health Care Campus and Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel.
Anticancer Res. 2016 Nov;36(11):6151-6154. doi: 10.21873/anticanres.11206.
Imatinib is generally well tolerated in the treatment of advanced gastrointestinal stromal tumors (GIST). Gastrointestinal vascular ectasia (GIVE) and gastric antral vascular ectasia (GAVE), while rare, are significant under-reported complications of imatinib therapy.
We present one patient with GIVE complicating imatinib therapy with a literature review of this rare side-effect.
A 68-year-old woman was diagnosed with advanced GIST, wild-type CKIT. After 3 months of treatment with imatinib, she had partial response. However, she was diagnosed with GAVE and, later, also with GIVE. During her 3-year imatinib treatment, she suffered from severe anemia and required blood transfusions. Conservative treatments were not helpful and the ectatic lesions resolved only with cessation of imatinib.
This confirms a causal relationship between GIVE and imatinib. GIVE and GAVE should be considered possible causes of anemia and upper gastrointestinal bleeding in patients receiving imatinib therapy.
伊马替尼在晚期胃肠道间质瘤（GIST）治疗中通常耐受性良好。胃肠道血管扩张症（GIVE）和胃窦血管扩张症（GAVE）虽然罕见，但却是伊马替尼治疗中报告不足的重要并发症。
我们报告1例伊马替尼治疗并发GIVE的患者，并对这种罕见的副作用进行文献综述。
一名68岁女性被诊断为晚期GIST，CKIT基因野生型。伊马替尼治疗3个月后，她出现部分缓解。然而，她被诊断出患有GAVE，后来又被诊断出患有GIVE。在她接受伊马替尼治疗的3年中，她患有严重贫血，需要输血。保守治疗无效，只有停用伊马替尼后扩张性病变才得以缓解。
这证实了GIVE与伊马替尼之间存在因果关系。GIVE和GAVE应被视为接受伊马替尼治疗患者贫血和上消化道出血的可能原因。
